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Abstract
Elderly adults have alterations in their gut microbiota and immune functions that are associated with higher susceptibility to infections and metabolic dis-
orders. Probiotics and prebiotics, and their synbiotic combinations are food supplements that have been shown to improve both gut and immune function.
The objective of this randomised, double-blind, placebo-controlled, cross-over human clinical trial was to study immune function and the gut microbiota in
healthy elderly adults. Volunteers (n 37) consumed prebiotic galacto-oligosaccharides (GOS; 8 g/d), probiotic Biﬁdobacterium lactis Bi-07 (Bi-07; 109 colony-
forming units/d), their combination (Bi-07 + GOS) and maltodextrin control (8 g/d) in four 3-week periods separated by 4-week wash-out periods.
Immune function was analysed by determining the phagocytic and oxidative burst activity of monocytes and granulocytes, whole-blood response to lipo-
polysaccharide, plasma chemokine concentrations and salivary IgA levels. Gut microbiota composition and faecal SCFA content were determined using
16S ribosomal RNA ﬂuorescence in situ hybridisation and HPLC, respectively. Primary statistical analyses indicated the presence of carry-over effects and
thus measurements from only the ﬁrst supplementation period were considered valid. Subsequent statistical analysis showed that consumption of Bi-07
improved the phagocytic activity of monocytes (P< 0·001) and granulocytes (P = 0·02). Other parameters were unchanged. We have for the ﬁrst time
shown that the probiotic Bi-07 may provide health beneﬁts to elderly individuals by improving the phagocytic activity of monocytes and granulocytes.
The present results also suggest that in the elderly, the effects of some probiotics and prebiotics may last longer than in adults.
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Of the population of Europe, 20 % are elderly (aged > 65
years) and this is predicted to increase to 25 % by 2020
according to the WHO. As individuals age, changes to
the physiology and function of the gastrointestinal tract
and immune system status occur(1). These changes are
associated with increased susceptibility to infections, meta-
bolic disorders and frailty that have signiﬁcant impact on
the quality of life in elderly individuals and healthcare
costs to society.
Although age-related changes have been shown in the com-
position, biodiversity and metabolic activities of the gut
microbiota, clear patterns of changes are still obscure due to
the impact of the environment and host on the microbiota(2–4).
For example, the amount of Bacteroides in the intestine has been
shown to both increase and decrease in elderly subjects
depending on the population studied(5–7). It is, however, well
established that with age the amount of facultative anaerobes
increases, such as opportunistic pathogens found in
Proteobacteria and Bacilli(5–9). Also, the number and diversity
of beneﬁcial biﬁdobacteria have been shown to decline in
some studies, indicating that a detrimental shift in the balance
of microbial species occurs with ageing(1,4).
Abbreviations: Bi-07, Biﬁdobacterium animalis subsp. lactis Bi-07; GOS, galacto-oligosaccharide; IFN, interferon; LPS, lipopolysaccharide; ROS, reactive oxygen species.
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Changes in the microbiota of the elderly are associated with
changes in the immune system status characterised by higher
production of pro-inﬂammatory cytokines(3). It was recently
shown that higher amounts of Bacilli and Proteobacteria in
the intestine are associated with increased IL-6 and IL-8
plasma levels in the elderly(3). Despite the increased levels of
pro-inﬂammatory cytokines, it seems that the reactivity of
the innate and adaptive immune systems in the elderly is
poorer. In vivo these ﬁndings are perhaps best highlighted by
low vaccination responses that lead to higher susceptibility
to infections(10,11). On a mechanism level, it has been shown
that ageing decreases toll-like receptor (TLR) signalling. For
example, lipopolysaccharide (LPS) signalling through TLR4
is impaired, leading to decreased cytokine production and
immune function(12) that could explain the reduced phagocytic
capacity of neutrophils in the elderly(11,13).
An appealing approach to modulate gut microbiota, poor
immune response and detrimental effects of the ageing popu-
lation is through the use of dietary interventions that have an
impact on both the gut microbiota and immune function.
Probiotics and prebiotics are widely accepted nutritional
supplements that have beneﬁcial effects on both microbiota
composition and potentially the immune system in the
elderly(14–16). Probiotics were deﬁned in 2001 by an FAO/
WHO workgroup as ‘live microorganisms which when admi-
nistered in adequate amounts confer a health beneﬁt on the
host’. A prebiotic is deﬁned as ‘a selectively fermented ingre-
dient that results in speciﬁc changes in the composition
and/or activity of the gastrointestinal microbiota, thus confer-
ring beneﬁt(s) upon host health’(17). Prebiotics are complex
oligosaccharides such as galacto-oligosaccharides (GOS), inu-
lin and fructo-oligosaccharides that are preferentially fermen-
ted by health-positive bacteria(18–21). This leads to changes in
the metabolism of the microbiota and in higher intestinal con-
centrations of beneﬁcial SCFA(15). Only a few clinical trials
have compared the effects of probiotics, prebiotics and their
synbiotic combinations in a single trial. In a recent study it
was concluded that changes to microbiota were different in
a resistant starch and Biﬁdobacterium lactis synbiotic group
than in prebiotic or probiotic groups in patients with colorectal
cancer(22). Another trial concluded that synbiotic (psyllium and
B. longum) administration improved the quality of life of ulcera-
tive colitis patients and decreased plasma C-reactive protein,
but this was not observed in probiotic or prebiotic groups(23).
In addition, in probiotic and prebiotic groups there were inde-
pendent effects on emotional and bowel function. These
studies suggest that synbiotic effects may not be additive,
although a study where GOS, B. lactis Bb-12 and their synbio-
tic were administered to healthy adults suggested that the syn-
biotic increases intestinal biﬁdobacteria numbers compared
with single products(24).
Consumption of probiotic B. lactis strains and GOS has
been shown to increase the number of biﬁdobacteria and to
improve phagocytic activity in elderly adults (B. lactis HN019
and trans-GOS)(24–26), indicating that consumption of B. lactis,
GOS and their synbiotic combination could improve health.
This clinical trial aims to study the impact of probiotic B. ani-
malis subsp. lactis Bi-07 (Bi-07), prebiotic GOS, synbiotic
Bi-07 + GOS and maltodextrin control on gut microbiota
and the immune system in healthy elderly adults. The study
was designed to follow supplementation-induced changes in
microbiota by analysing marker bacterial groups and SCFA
from faecal samples. Changes in inﬂammatory status and
immune system responsiveness by the supplementation were
analysed by measuring the concentration of inﬂammatory
chemokines in plasma and the responsiveness of isolated
peripheral blood mononuclear cells to LPS, respectively.
Furthermore, phagocytic and oxidative burst activity of mono-
cytes and granulocytes was analysed to associate changes in
microbiota and immune cell responsiveness with the function
of phagocytic cells.
Experimental methods
Trial design
A total of forty-one healthy elderly volunteers were screened
for inclusion to trial. Of these, forty were found to be eligible
for the study and were randomly divided into four groups. A
double-blinded, placebo-controlled, randomised cross-over
study was designed where volunteers received maltodextrin
(8 g/d; Syral), prebiotic GOS (8 g/d; Danisco), probiotic
(Bi-07; 109 colony-forming units/d; Danisco) and synbiotic
GOS + Bi-07 (8 g GOS/d and 109 colony-forming units
Bi-07/d). The daily portions were based on dose–response
clinical studies showing that an 8 g portion of GOS has a biﬁ-
dogenic effect(27) and that 109 colony-forming units of B. lactis
induce changes in elderly microﬂora(28). Volunteers were
randomised to groups that consumed the study products in
a predeﬁned order: group 1, prebiotic–synbiotic–maltodextrin–
probiotic; group 2, synbiotic–maltodextrin–probiotic–prebiotic;
group 3, maltodextrin–probiotic–prebiotic–synbiotic; group 4,
probiotic–prebiotic–synbiotic–maltodextrin. Supplements were
provided for 21 d, with a 28 d wash-out period that has been
effective in previous studies with B. lactis and GOS(24,25,27)
(Fig. 1). Compliance was not measured. The trial was regis-
tered at Clinicaltrials.gov as NCT01586247.
Volunteers
The present study was conducted according to guidelines laid
down in the Declaration of Helsinki and all procedures invol-
ving human subjects were approved by the Research Ethics
Committee of the University of Reading. Written informed
consent was obtained from all subjects. Volunteers were
recruited from the Reading area. Inclusion criteria were: a
signed consent form, age over 60 years, not in residential
care, and good general health as determined by medical ques-
tionnaires. Exclusion criteria included evidence of physical or
mental disease or planned major surgery or use of antibiotics
within the previous 6 months. Subject characteristics are
described in Table 1. Volunteers attended study appointments
before and after each treatment and wash-out period. At study
appointments, anthropometric measurements were recorded
(weight, blood pressure, waist circumference) and volunteers
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provided a fasted blood sample (collected into heparinised
tubes), and samples of saliva and faeces (Fig. 1).
Study products
The GOS product was synthesised at 55°C (pH 5·0) by 50
acid lactase units (ALU) β-galactosidase-1/g from Aspergillus
oryzae GC288 using 55 % (w/v) lactose (Dairy Crest) as a sub-
strate. The GOS product yield was 32·45 % (w/w). The pro-
duct had predominantly Gal(β1–6), Gal(β1–4) and Gal(β1–3)
linkages. Bi-07 (ATCC SD5220; American Type Culture
Collection) was produced according to good manufacturing
practice at the Madison plant by Danisco. The maltodextrin
was generously provided by Syral. The products were con-
sumed daily by the subjects as provided in individual daily
dose sachets in powder form.
Sample size determination and randomisation
The study group size was estimated by least standardised
difference (LSD) using expected changes in the microbial
population and faeces as the primary outcome. On the
basis of a 5 % signiﬁcance level, a power of 95 % for
detecting the main effect and two-factor interactions, with a
standardised size effect of 0·85 or more, a sample size of
eight per treatment per group was required. A total of ten
per group were included in the study to allow for potential
study ‘drop-out’. Blinding was done by Danisco and ran-
domisation to study groups 1–4 by the investigators.
Statistical analysis
The data from the cross-over study were analysed using linear
ﬁxed-effects models with ﬁxed effect terms for the presence/
absence of prebiotic/probiotic treatment and their interaction
(i.e. a 2 × 2 factorial approach), and a baseline regression coef-
ﬁcient accounting for individual baseline differences between
the subjects. Based on the residual analysis, some variables
were transformed using logarithmic, square root or power
transformations. All the treatments related to statistically sig-
niﬁcant factors in the linear models (P < 0·05) were further
statistically compared using contrasts for the linear models.
The number of contrasts depended on the statistically signiﬁ-
cant terms, and the obtained P values were adjusted for mul-
tiple comparisons using a single-step algorithm.
The linear model analyses were conducted with R: A
Language and Environment for Statistical Computing (version
2.14.2; R Development Core Team) using packages nlme:
Fig. 1. Schematic overview of the study design. MDX, maltodextrin; GOS, galacto-oligosaccharides; Bi-07, Bifidobacterium animalis subsp. lactis Bi-07.
Table 1. Baseline characteristics of volunteers in a double-blind, placebo-controlled, randomised cross-over study of a candidate prebiotic
(galacto-oligosaccharides; GOS; 8 g/d), probiotic (Bifidobacterium animalis subsp. lactis Bi-07 (Bi-07); 109 colony-forming units/d) or synbiotic (GOS +
Bi-07)
(Mean values with their standard errors, or number of subjects)
Maltodextrin (n 9) Prebiotic (n 9) Probiotic (n 8) Synbiotic (n 10)
Mean SEM Mean SEM Mean SEM Mean SEM P
Sex (n)
Male 4 3 5 5
Female 5 6 3 5 0·69
Age (years) 63·0a 0·5 70·7b 0·69 64·6a 0·5 70·5b 1·3 <0·001
Weight (kg) 76·5 4·5 74·5 3·3 73·8 5·4 75·0 4·3 0·98
BMI (kg/m2) 25·6 1·3 28·4 1·1 25·6 1·2 25·2 1·4 0·27
Plasma cholesterol (mM) 5·8 0·5 5·6 0·3 5·3 0·2 6·0 0·4 0·66
a,b Mean values within a row with unlike superscript letters were significantly different (P < 0·05).
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Linear and Nonlinear Mixed Effects Models (version 3.1-103;
J. Pinheiro, D. Bates, S. DebRoy, D. Sarkar and R
Development Core Team), and multcomp (version 1.2.12)(29).
Phagocytosis and oxidative burst
Phagocytosis and oxidative burst by monocytes and granulo-
cytes were determined in fresh (4–6 h) heparinised whole-
blood samples using PHAGOTEST® and BURSTTEST®
(ORPEGEN Pharma) in accordance with the manufacturer’s
instructions. Escherichia coli, provided by the manufacturer,
were opsonised with complement and immunoglobulins
using pooled sera, and were labelled with ﬂuorescein isothio-
cyanate (FITC). In brief, E. coli were incubated for 10 min in
heparinised whole blood at 37°C. Phagocytosis was stopped
by placing the sample on ice and by adding a solution that
quenches extracellularly bound FITC–E. coli. Erythrocytes
were lysed and sample washed. Using a ﬂow cytometer
(FACSCalibur, BD Biosciences), monocytes and granulocytes
were identiﬁed based upon their characteristic appearance on
a FSC/SSC (forward scatter versus side scatter) plot. The per-
centages of phagocytes that had ingested bacteria (ﬂuorescent/
total) and had phagocytic activity (number of bacteria per
cell as determined by mean ﬂuorescence intensity) were
determined.
In BURSTTEST®, complement and immunoglobulin-
opsonised E. coli as provided by the manufacturer were incu-
bated with heparinised whole blood for 10 min at 37°C.
Fluorogenic dihydrorhodoamine-123, which reacts with reac-
tive oxygen species (ROS), was added to the sample and incu-
bated for 10 min at 37°C. The reaction was stopped by adding
an erythrocyte-lysing solution. After washing, the monocytes
and granulocytes were identiﬁed by means of an FSC/SSC
plot using a ﬂow cytometer (FACSCalibur; BD Biosciences).
The production of reactive oxygen metabolites within mono-
cytes and granulocytes was determined by counting the
percentage of ﬂuorescent cells and their mean ﬂuorescence
intensity, which correlates with ROS production.
Immune assays
Cytokine and chemokine concentrations were determined using
commercially available bead-arrays from BenderMedSystems
which both utilise sandwich ELISA technology. All immune
assays were conducted to conform to an intra-assay CV of
<10 % and an inter-assay CV of <20 %. Sample concen-
trations were calculated using an eight-point standard curve.
LPS-stimulated cytokine production was analysed in 1/10
diluted whole blood. Roswell Park Memorial Institute
(RPMI)-1640 media containing HEPES and L-glutamine
(Lonza) was used, to which streptomycin (1 mg/ml) and
penicillin (62·5 µg/ml) were added. Cultures were incubated
for 24 h in the presence of LPS from E. coli O111:B4
(1 µg/ml; Sigma Aldrich). Culture supernatant fractions were
assessed for cytokine production using a Th1/Th2 cytokine
array (Bender MedSystems) in accordance with the manufac-
turer’s instructions. This array includes interferon (IFN)-γ,
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, TNF-α
and TNF-β. The levels of IL-2, IL-4, IL-5, IL-12p70, and
TNF-β were below detection levels in most of the samples
(data not presented).
Plasma chemokines were assessed using a human chemo-
kine 6-plex kit (Bender MedSystems) in accordance with the
manufacturer’s instructions. This array includes granulocyte-
colony stimulating factor (G-CSF), monocyte chemotactic
protein-1 (MCP-1), monokine induced by interferon-γ
(MIG), macrophage inﬂammatory protein 1-α (MIP1-α) and
macrophage inﬂammatory protein 1-β (MIP1-β).
Saliva samples were collected by expectoration in the morn-
ing by fasted participants. Samples were centrifuged at 1000 g
for 10 min and supernatant fractions stored at –20°C before
analysis. Salivary IgA content was determined by sandwich
ELISA (Immunodiagnostik) in accordance with the manufac-
turer’s instructions.
Faecal sample processing
Freshly voided faecal samples were collected in sterile plastic
containers. Samples were stored at room temperature under
anaerobic conditions before processing, which typically com-
menced within 4 h of sample receipt. Samples for use in faecal
dry weight and IgA assays were stored at –20°C, and samples
for quantitative PCR and enumeration of total bacteria by ﬂow
cytometry stored at –80°C. Remaining faecal samples were
diluted 1 in 10 (w/w) in PBS (0·1 M; pH 7·0) and homogenised
in a Stomacher 400 (Seward) for 2 min at normal speed (460
paddle beats per min). A 15 ml sample of faecal slurry was
vortexed with 2 g of 3-mm diameter glass beads (VWR
International) and then centrifuged to remove particulate mat-
ter (1500 g; 2 min). The supernatant fraction was collected for
use in SCFA analysis and assessment of genus-level changes in
the gut microbiota by ﬂuorescence in situ hybridisation with
16S ribosomal RNA targeted oligonucleotide probes.
Fluorescence in situ hybridisation
The faecal slurry supernatant fraction was ﬁxed in paraformal-
dehyde (1:4 (v/v) in 4 % paraformaldehyde in 0·1 M-PBS, pH
7·2) for 4 h at 4°C, centrifuged (13 000 g; 5 min), washed twice
with 0·1 M-PBS, re-suspended in 1:1 PBS–ethanol and stored at
–20°C. Oligonucleotide probes used were Cy-3 labelled and
synthesised by Sigma-Aldrich. Probes used were Bif164,
Bac303, Chis150, Lab158 and ATO291, Erec482, Fprau655,
Enter1432 and Strc493 speciﬁc for Biﬁdobacterium spp.,
Bacteroides–Prevotella group, Clostridium clusters I and II (includ-
ing Clostridium perfringens and C. histolyticum), Lactobacillus–
Enterococcus subgroup, Atopobium cluster, Eubacterium rectale–
Blautia coccoides group, Faecalibacterium cluster, Enterobacterium
group and Streptococcus group–Lactococcus, respectively(30–36).
Samples were hybridised as described by Costabile et al.(37).
Data are expressed as log10 counts per g dry faeces.
Quantification of Bifidobacterium lactis
DNA was extracted from the faecal samples with the use of
the QIAamp DNA stool Mini kit (Qiagen) following the man-
ufacturer’s instructions. Quantitative PCR was used for
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quantiﬁcation of B. lactis using the FAST SYBR green method-
ology (Applied Biosystems) in a total volume of 25 µl contain-
ing 1 ng of template DNA and 250 nM of the forward primer
Blact_1(38) and reverse primer Bﬂact5(39). The ampliﬁcation
and detection of DNA were performed with an ABI 7500
sequencing detection system (Applied Biosystems). To obtain
standard curves, a 10-fold dilution series ranging from 10 pg
to 10 ng of DNA from the bacterial standard cultures was
included in the PCR assays. For determination of DNA, tripli-
cate samples were used, and the mean quantity per g wet
weight was calculated.
Organic acids
Filter-sterilised samples (1 ml) of faecal slurry (10 % (w/v)
dilution of freshly voided faeces in PBS; pH 7·0) were used
to determine faecal concentrations of organic acids including
acetic acid, propionic acid, i-butyric acid, n-butyric acid,
i-valeric acid, n-valeric acid, n-caproic acid and D-/L-lactic
acid by HPLC. The column was an ion-exclusion
REZEX-ROA organic acid column (7·8 × 300 nm;
Phenomenex) maintained at 85°C. The eluent was 0·0025
mM-sulfuric acid in HPLC-grade water and the ﬂow rate was
0·6 ml/min. Quantiﬁcation of the samples was obtained
through calibration curves of acetic acid, formic acid, propio-
nic acid, butyric acid and lactic acid in concentrations between
6·25 and 100 mM.
Results
Subject characteristics
Recruitment of forty-one subjects for the study took place in
the Reading area of the UK. Of these, forty volunteers passed
the inclusion/exclusion criteria and started the trial in March
2008; thirty-seven completed the trial in October 2009.
However, one subject was removed from the statistical analysis
due to missing samples, resulting in a study size of thirty-six
subjects (see the Sample size determination and randomisation
section, Table 1 and Fig. 1).
Analyses of baseline drift, carry-over effect and subject
characteristics
Stability of the baseline was studied by comparing results
from samples on day –5 (baseline) and on day 0 (before
ﬁrst supplementation). Using independent-samples t tests it
was found that six out of forty parameters had signiﬁcantly
different levels (P < 0·05) on day 0 than on day –5 in some
supplementation groups (Table 2). These results indicate that
the baselines within the groups were not stable.
Carry-over effects are a known problem in clinical trials with
a cross-over design. Samples from day 0 (before ﬁrst sup-
plementation) and day 49 (after the ﬁrst wash-out) were ana-
lysed for similarity using independent-samples t tests. By
using P < 0·05 as a cut-off, it was found that in eleven out
of forty parameters the values did not return to pre-
supplementation levels in some groups (Table 2). It was
concluded that carry-over effects might bias the results and
thus statistical analysis was conducted for parallel groups
using results from samples obtained on day 0 (before the
ﬁrst supplementation) and on day 21 (after the ﬁrst
supplementation).
The change in study design from cross-over to parallel
resulted in an unbalanced age distribution between the study
groups. Subjects in the maltodextrin and probiotic groups
were of similar age, but subjects in the prebiotic and synbiotic
groups were on average 6·8 years younger (P < 0·001)
(Table 1).
Activity of peripheral blood monocytes and granulocytes
The supplementations did not change the percentages of
monocytes and granulocytes engaged in phagocytosis com-
pared with maltodextrin (Fig. 2(a) and 2(b)); however, there
was a higher percentage of phagocytosing monocytes in the
probiotic group compared with the prebiotic (P = 0·005)
group (Fig. 2(a)). Phagocytic activity of monocytes in the pro-
biotic group was higher than in the maltodextrin (P < 0·001)
or prebiotic groups (P < 0·001) (Fig. 2(c)). Furthermore, a
higher phagocytic activity of granulocytes was found in the
probiotic (P = 0·02) supplementation group compared with
the maltodextrin group (Fig. 2(d)).
The BURSTTEST® assay was used to measure the presence
of ROS in phagocytes after incubation of opsonised E. coli in
whole blood from the study subjects. The proportion of
monocytes and granulocytes producing ROS was not affected
by the supplementations compared with maltodextrin (Fig. 3(a)
Table 2. Parameters having baseline drift or carry-over effects
Parameter
Treatment
group
Baseline
drift
Carry-over
effect
Bifidobacterium lactis Prebiotic ✓
Bacteroides–Prevotella Probiotic ✓
Blautia coccoides–
Eubacterium rectale
cluster
Probiotic ✓ ✓
Enterobacteria Prebiotic ✓ ✓
Faecalibacterium prausnitzii
cluster
Synbiotic ✓
Faecalibacterium prausnitzii
cluster
Probiotic ✓
IL-8 Probiotic ✓
Lactobacillus–Streptococcus
group
Probiotic ✓
Oxidative burst activity of
monocytes
Probiotic ✓
Percentage of granulocytes
having oxidative burst
activity
Placebo ✓
Percentage of monocytes
having phagocytic activity
Placebo ✓
Prebiotic ✓ ✓
Probiotic ✓
Synbiotic ✓
Phagocytic activity of
monocytes
Placebo ✓ ✓
Probiotic ✓
Total bacteria Probiotic ✓
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and 3(b)), nor was oxidative burst activity of these cells (Fig. 3
(c) and 3(d)). However, the percentage of monocytes produ-
cing ROS in the probiotic group was higher than in the synbio-
tic group (P = 0·04) (Fig. 3(a)).
Lipopolysaccharide stimulation of the whole blood and soluble
immune markers
Immune markers were analysed from saliva, plasma, and by
stimulating heparinised whole blood with LPS. The levels of
cytokines in whole blood, chemokine concentrations in plasma
and IgA levels in saliva were unaltered by the treatments
(online Supplementary Table S1).
Composition and metabolic function of the intestinal
microbiota
Microbiota compositions of the subjects were characterised
using 16S ribosomal RNA targeted ﬂuorescence in situ hybrid-
isation for the selected marker species or quantitative PCR for
the determination of B. lactis (Table 3). Composition of the
microbiota did not signiﬁcantly change in any of the treatment
groups. Metabolic activity of the microbiota was measured by
analysing organic acid concentrations in the faeces, but there
was no signiﬁcant effect of any of the treatments (online
Supplementary Table S2).
Discussion
A randomised placebo-controlled cross-over clinical trial was
designed to study the effect of probiotic Bi-07, prebiotic
GOS or their synbiotic combination Bi-07 +GOS on gut
and immune functions in healthy non-institutionalised elderly
adults. It was found that the baseline of some of the par-
ameters drifted before supplementation (Table 2), which
could indicate natural ﬂuctuation in this population. In
addition, statistical analyses of the cross-over study revealed
signiﬁcant carry-over effects on indices of microbiota and
immune function (Table 2), indicating that a 4-week wash-out
period was not sufﬁcient in this trial. In a similar study set-up,
the effect of GOS syrup (8·1 g GOS/d), B. lactis Bb-12 and
their combination was studied on biﬁdobacteria numbers in
healthy adults. It was found that Bb-12 and Bb-12 + GOS
syrup supplementation increased biﬁdobacteria amounts, but
Fig. 2. Phagocytic activity of monocytes and granulocytes. Phagocytic activity was measured using a flow cytometer after incubation of opsonised and fluorescence-
labelled Escherichia coli in whole blood of the subjects. Percentage of monocytes (a) and granulocytes (b) of the total population that had phagocytosed E. coli.
Phagocytic activity of monocytes (c) and granulocytes (d) measured as fluorescence intensity in individual cells that had phagocytosed E. coli. Statistical differences
were calculated using linear model contrasts. Whiskers represent the minimum and maximum values; the box represents the 25th percentile, median and 75th per-
centile; + indicates the mean value. Mean value was significantly different from that of the maltodextrin group: *P = 0·02, **P < 0·001. Mean value was significantly
different from that of the prebiotic group: †P = 0·005, ††P < 0·001.
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the levels returned to normal after a 2-week wash-out
period(24). Another study has also shown that after 2 weeks
of wash-out, Bb-12 could be recovered from the faeces of
only a few individuals, indicating transient colonisation of
B. lactis in healthy adults(40). Furthermore, two recent studies
utilising pyrosequencing showed that 2 weeks after GOS
supplementation the microbiota composition returned to base-
line levels in healthy adults(41,42). Taken together, the results of
these studies suggest that a 2-week wash-out period is long
enough in healthy adults. In the present study, however, an
Fig. 3. Oxidative burst activity of phagocytes. Oxidative burst activity was measured using a flow cytometer after incubation of opsonised and fluorescence-labelled
Escherichia coli in whole blood of the subjects. Percentage of monocytes (a) and granulocytes (b) of the total population showing oxidative burst activity. Oxidative
burst activity of monocytes (c) and granulocytes (d) measured as fluorescence intensity in individual cells that had oxidative burst activity. Statistical differences were
calculated using linear model contrasts. Whiskers represent the minimum and maximum values; the box represents the 25th percentile, median and 75th percentile;
+ indicates the mean value. ‡Mean value was significantly different from that of the probiotic group (P = 0·04).
Table 3. Gut microbiota of volunteers during treatment with placebo, a prebiotic (galacto-oligosaccharides; GOS; 8 g/d), probiotic (Bifidobacterium animalis
subsp. lactis Bi-07 (Bi-07); 109 colony-forming units/d) or synbiotic (GOS + Bi-07) at the end of the first 21 d treatment period
(Mean values with their standard errors)
Treatment
Maltodextrin (n 9)
(log10 cells/g
faeces)
Prebiotic (n 9)
(log10 cells/g
faeces)
Probiotic (n 8)
(log10 cells/g
faeces)
Synbiotic (n 10)
(log10 cells/g
faeces)
Bacterial group Mean SEM Mean SEM Mean SEM Mean SEM
Atopobium cluster 10·3 0·10 10·2 0·10 10·1 0·05 10·1 0·06
Bacteroides–Prevotella 10·6 0·07 10·4 0·15 10·6 0·08 10·4 0·08
Bifidobacterium group 10·1 0·13 9·7 0·20 9·4 0·39 9·9 0·13
Bifidobacterium lactis 5·7 0·25 6·0 0·22 6·3 0·22 6·2 0·30
Clostridium clusters I and II 8·8 0·24 8·1 0·27 8·9 0·43 7·9 0·27
Blautia coccoides–Eubacterium rectale cluster 10·7 0·07 10·6 0·10 10·8 0·06 10·5 0·06
Enterobacteria 9·5 0·31 9·1 0·27 9·2 0·41 9·4 0·17
Faecalibacterium prausnitzii cluster 10·5 0·05 10·3 0·12 10·5 0·04 10·4 0·09
Lactobacillus–Streptococcus group 9·2 0·24 8·6 0·14 9·4 0·16 8·6 0·10
Total bacteria 11·3 0·09 11·2 0·12 11·3 0·07 11·2 0·06
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elderly population was studied and it may be that probiotic and
prebiotic supplementation induces longer-lasting changes in
elderly microbiota than in adults. Interestingly, in a series of
papers, elderly subjects were supplemented with B. lactis
HN019 or Lactobacillus rhamnosus HN001 and after a 3-week
wash-out period several immune indices were numerically
higher than at baseline; however, unfortunately, wash-out time
points were not statistically compared with baseline(25,43,44).
To eliminate cross-over effects, samples from only the ﬁrst
supplementation period were used in the subsequent statistical
analyses, making the statistical analysis design parallel instead
of cross-over. This resulted in a higher average age in the mal-
todextrin and probiotic groups compared with in the prebiotic
and synbiotic groups. As it is known that microbiota compo-
sition and immunological functions decline during ageing, the
prebiotic and synbiotic efﬁcacy (or not) is merely speculative in
the present study. However, the comparison of the maltodex-
trin control with the probiotic seems to be valid.
It was found that consumption of Bi-07 improved the
phagocytic activity of monocytes and granulocytes against
complement and immunoglobulin-opsonised E. coli (Fig. 2(c)
and 2(d)). In previously published clinical trials, enhanced
phagocytosis in healthy elderly adults has been shown for
Biﬁdobacterium animalis subsp. lactis HN019(25,45) and also in
healthy adults for strains Bb-12 and HN019 of the same
species(46,47). These studies support the results observed for
Bi-07 in the present trial and indicate a positive effect of B. lac-
tis consumption on phagocytic activity in general that could
potentially lead to improved immune responses against infec-
tive agents.
Although improved phagocytic activity was observed in the
probiotic group (Fig. 2(c) and 2(d)), it did not lead to higher
intracellular ROS generation than what was observed for the
maltodextrin group (Fig. 3(c) and 3(d)). This result was sup-
ported by similar pro-inﬂammatory cytokine response levels
to LPS (TNF-α, IFN-γ, IL-1β, IL-6, and IL-8) and stable che-
mokine levels in plasma (online Supplementary Table S1) in
the maltodextrin and probiotic groups. On the other hand,
probiotic supplementation did not improve anti-inﬂammatory
IL-10 production either (online Supplementary Table S1).
Previous in vitro studies have shown that in comparison with
other Biﬁdobacterium and Lactobacillus strains, Bi-07 is among
the most potent inducers of IL-12p70 and IFN-γ from
human peripheral blood monocytes(48). IFN-γ and IL-12p70
are prototypical cytokines involved in activating Th1-type
immune responses that enhance phagocytosis and intracellular
killing of microbes. On the other hand, Bi-07 also induced a
moderate amount of IL-10 from peripheral blood mono-
nuclear cells and protected mice from trinitrobenzene sulfonic
acid (TNBS)-induced colitis(48), which could explain the null
impact on ROS generation. This type of non-inﬂammatory
phagocytosis is an important mechanism of maintaining
homeostasis in the gut mucosa where overt reactions to com-
mensal microbes may lead to conditions such as inﬂammatory
bowel disease.
In the present randomised clinical trial on healthy elderly
adults, the probiotic Bi-07 had a positive impact on the phago-
cytic activity of monocytes and granulocytes in the elderly
subjects without increasing the release of ROS.
Consumption of Bi-07 could potentially improve clearance
of bacteria from the body without contributing to the low-
grade inﬂammation observed in the elderly population(49).
Thus, consumption of the probiotic Bi-07 may provide long-
term health beneﬁts for the elderly by not contributing to
inﬂammation-associated metabolic disorders while enhancing
the innate immune defence against infections.
The present results indicate that the wash-out time of sup-
plementation may need to be longer in elderly subjects than
what has been shown for adults. Overall, it is likely that the
effective time of the probiotics and prebiotics on the gut
microbiota and immune function is dependent on the popu-
lation, diet, and on the properties of the probiotics and prebio-
tics themselves. It is clear that well-designed clinical trials on
the effects of probiotics, prebiotics and synbiotics on health
are acutely needed.
Supplementary material
To view supplementary material for this article, please visit
http://dx.doi.org/10.1017/jns.2013.31
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